Renin‐angiotensin system inhibition vs supportive treatment: > 50% increase in SCr
- Population
- people IgA nephropathy
- Intervention
- Renin‐angiotensin system inhibition
- Comparison
- supportive treatment
- Outcome
- > 50% increase in SCr
Renin‐angiotensin system inhibition may leads to lower > 50% increase in SCr compared with other supportive care treatment (low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Renin‐angiotensin system inhibition vs other supportive care treatment > 50% increase in SCr · people IgA nephropathy Renin‐angiotensin system inhibition may leads to lower > 50% increase in SCr compared with other supportive care treatment (low certainty). Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane Headline outcomes only | RR 0.23 [0.07, 0.7] | 1 study · 44 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Non‐immunosuppressive treatment for IgA nephropathy 2024 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- Renin‐angiotensin system inhibition vs placebo or no treatment · people IgA nephropathy · 1 review
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.